View ICR - OIRA Conclusion



0925-0664 201505-0925-002
Historical Active 201505-0925-001
HHS/NIH 21181
Population Assessment of Tobacco and Health (PATH) Study (NIDA)
No material or nonsubstantive change to a currently approved collection   No
Regular
Approved without change 06/15/2015
Retrieve Notice of Action (NOA) 05/21/2015
Previous terms continue: This approval covers Wave 2 of PATH. A full revision is necessary for the collection of Wave 3 data. Before submitting the information collection request for Wave 3 to OMB, NIDA/FDA should report to OMB regarding: a) the response rates associated with the full baseline wave, including screening, interview completion, and bio-specimen response; b) Wave 2 retention, recruitment rates for the “age in to adult” and “age in of shadow” subsamples; c) the results of nonresponse analysis and statistical approach for addressing non-response, as well as implications for the study going forward; and d) the statistical approach to be applied to the bio-specimen data to address potential non-response bias from lower consent and cooperation rates with this aspect of the study. Per prior terms of clearance, NIDA and FDA will create a public use dataset from each wave’s data, making it available to the public on-line within 18 months of completion of each wave. Data underlying government-funded scientific publications will be made available to the public, consistent with NIH guidelines for implementing OSTP’s Public Access to the Results of Federally Funded Research. This study is not specifically designed to provide nationally representative estimates of prevalence. As such, FDA and NIDA will always present such cross-sectional prevalence estimates in conjunction with estimates from HHS’ signature nationally representative studies such as CPS-TUPS, NHIS, NATS, and NSDUH.
  Inventory as of this Action Requested Previously Approved
09/30/2016 09/30/2016 09/30/2016
192,858 0 192,858
59,023 0 58,340
0 0 0